The impact of obesity on cardiovascular and kidney outcomes in patients with chronic kidney disease and type 2 diabetes treated with finerenone: Post hoc analysis of the FIDELITY study
Authors' conclusion
In FIDELITY, benefits of finerenone in lowering the risk of cardiovascular and kidney outcomes were not significantly modified by patient obesity.
Study context
- Population
- Patients with CKD and T2D, stratified by waist circumference (WC) risk group (visceral obesity): low-risk or high-very high-risk (H-/VH-risk); 90.8% H-/VH-riskanalysed
- Participants
- 12,986 patients
- Comparison
- Finerenone vs placebo, by WC risk group
- Primary endpoint
- Composite cardiovascular and kidney outcomes, by WC risk group
Methodological detailsprespecified pooled dataset, subgroup analysis by waist circumference
- Prespecified pooled dataset
- Subgroup analysis by waist circumference
Primary result
As reported in the abstract
Composite:
- Cardiovascular
- Kidney outcomes by WC risk group
Finerenone vs PlaceboHazard ratio (95% CI)
CV composite, low-risk WC
1.03(0.72–1.47)
CV composite, H-/VH-risk WC
0.85(0.77–0.93)
Kidney composite, low-risk WC
0.98(0.66–1.46)
Kidney composite, H-/VH-risk WC
0.75(0.65–0.87)
- Heterogeneity between WC groups, CV composite
- P for interaction = 0.26
- Heterogeneity between WC groups, kidney composite
- P for interaction = 0.34
Safety
- Adverse events were consistent across WC groups
Original publication
The impact of obesity on cardiovascular and kidney outcomes in patients with chronic kidney disease and type 2 diabetes treated with finerenone: Post hoc analysis of the FIDELITY study. Diabetes Obes Metab. Published 4 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →